Nicolas Penel


Ontology type: schema:Person     


Person Info

NAME

Nicolas

SURNAME

Penel

Publications in SciGraph latest 50 shown

  • 2018-12 Once weekly paclitaxel associated with a fixed dose of oral metronomic cyclophosphamide: a dose-finding phase 1 trial in BMC CANCER
  • 2018-12 Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial in BMC CANCER
  • 2018-05 Genome profiling is an efficient tool to avoid the STUMP classification of uterine smooth muscle lesions: a comprehensive array-genomic hybridization analysis of 77 tumors in MODERN PATHOLOGY
  • 2018-03 Efficacy and safety of 153Sm-EDTMP as treatment of painful bone metastasis: a large single-center study in SUPPORTIVE CARE IN CANCER
  • 2017-12 A Retrospective Multicentric Study of Ewing Sarcoma Family of Tumors in Patients Older Than 50: Management and Outcome in SCIENTIFIC REPORTS
  • 2016-12 PRognostic factor of Early Death In phase II Trials or the end of ‘sufficient life expectancy’ as an inclusion criterion? (PREDIT model) in BMC CANCER
  • 2016-12 Auto-immune thyroid dysfunction induced by tyrosine kinase inhibitors in a patient with recurrent chordoma in BMC CANCER
  • 2016-06 Dose-Seeking Phase I Trials for Currently Approved Molecular-Targeted Therapies in the USA: The Dose-Limiting Toxicity Definition Issue in PHARMACEUTICAL MEDICINE
  • 2016-06 Sorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II study in BRITISH JOURNAL OF CANCER
  • 2016-02 Early Trial Discontinuation in Toxicity-Driven, Dose-Escalating, Phase I Cancer Trials: Occurrence, Outcomes and Predictive Factors in PHARMACEUTICAL MEDICINE
  • 2015-12 Study protocol of REGOSARC trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase II trial in BMC CANCER
  • 2015-12 Improvement of the initial management of sarcomas after the dissemination of evidence-based guidelines depends on the primary sarcoma location: a population-based study in BMC CANCER
  • 2015-12 Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group in BMC CANCER
  • 2014-12 The off-label use of targeted therapies in sarcomas: the OUTC’S program in BMC CANCER
  • 2014-09 Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trial in TARGETED ONCOLOGY
  • 2014-06 Mechanisms of resistance to imatinib mesylate in KIT-positive metastatic uveal melanoma in CLINICAL & EXPERIMENTAL METASTASIS
  • 2014-02 Phase I dose-escalation study of oral vinflunine in combination with erlotinib in pre-treated and unselected EGFR patients with locally advanced or metastatic non-small-cell lung cancer in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2013-12 Efficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systematic review in BMC CANCER
  • 2013-12 Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program in BMC CANCER
  • 2013-12 Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO) in INVESTIGATIONAL NEW DRUGS
  • 2013-11 A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted olid tumours in BRITISH JOURNAL OF CANCER
  • 2013-08 A phase I, open-label, single-arm study for QT assessment of eribulin mesylate in patients with advanced solid tumors in INVESTIGATIONAL NEW DRUGS
  • 2013-08 A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group in BRITISH JOURNAL OF CANCER
  • 2013-04 Transgelin is a novel marker of smooth muscle differentiation that improves diagnostic accuracy of leiomyosarcomas: a comparative immunohistochemical reappraisal of myogenic markers in 900 soft tissue tumors in MODERN PATHOLOGY
  • 2012-12 Serum creatine kinase increase in patients treated with tyrosine kinase inhibitors for solid tumors in MEDICAL ONCOLOGY
  • 2012-12 What does a modified-Fibonacci dose-escalation actually correspond to? in BMC MEDICAL RESEARCH METHODOLOGY
  • 2012-09 Prediction of early death among patients enrolled in phase I trials: development and validation of a new model based on platelet count and albumin in BRITISH JOURNAL OF CANCER
  • 2012-04 Predictors for establishing recommended phase 2 doses: analysis of 320 dose-seeking oncology phase 1 trials in INVESTIGATIONAL NEW DRUGS
  • 2012-02 Circulating thrombospondin 1 level as a surrogate marker in patients receiving cyclophosphamide-based metronomic chemotherapy in INVESTIGATIONAL NEW DRUGS
  • 2011-12 Nature and subjectivity of dose-limiting toxicities in contemporary phase 1 trials: comparison of cytotoxic versus non-cytotoxic drugs in INVESTIGATIONAL NEW DRUGS
  • 2011-12 Adjuvant radiation therapy in metastatic lymph nodes from melanoma in RADIATION ONCOLOGY
  • 2011-08 Proposal for size justification of expanded cohort at phase-2-recommended dose in INVESTIGATIONAL NEW DRUGS
  • 2011-08 Factual understanding of randomized clinical trials: a multicenter case-control study in cancer patients in INVESTIGATIONAL NEW DRUGS
  • 2011-05 Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcomaThe European Organisation for Research and Treatment of Cancer – Soft Tissue and Bone Sarcoma Group (STBSG) and French Sarcoma Group (FSG) study in BRITISH JOURNAL OF CANCER
  • 2011-03 Imaging of the most frequent superficial soft-tissue sarcomas in SKELETAL RADIOLOGY
  • 2010-12 Justification of the starting dose as the main determinant of accrual time in dose-seeking oncology phase 1 trials in INVESTIGATIONAL NEW DRUGS
  • 2010-10 Oral metronomic cyclophosphamide in elderly with metastatic melanoma in INVESTIGATIONAL NEW DRUGS
  • 2010-08 Inadequacy of size-based response criteria to assess the efficacy of trabectedin among metastatic sarcoma patients in INVESTIGATIONAL NEW DRUGS
  • 2010-08 Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis in BRITISH JOURNAL OF CANCER
  • 2010-04 Megestrol acetate versus metronomic cyclophosphamide in patients having exhausted all effective therapies under standard care in BRITISH JOURNAL OF CANCER
  • 2010-04 Phase II trials in patients with carcinoma of unknown primary: a pooled data analysis in INVESTIGATIONAL NEW DRUGS
  • 2010-02 Development and validation of a model that predicts early death among cancer patients participating in phase I clinical trials investigating cytotoxics in INVESTIGATIONAL NEW DRUGS
  • 2010 Méthodes radiologiques d’évaluation de la réponse thérapeutique en cancérologie in CANCER DU SEIN EN SITUATION MÉTASTATIQUE
  • 2009-12 “Classical 3 + 3 design” versus “accelerated titration designs”: analysis of 270 phase 1 trials investigating anti-cancer agents in INVESTIGATIONAL NEW DRUGS
  • 2009-10 Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma in INVESTIGATIONAL NEW DRUGS
  • 2009-08 Cancer-associated hypercalcemia: validation of a bedside prognostic score in SUPPORTIVE CARE IN CANCER
  • 2009-06 Publication biases and phase II trials investigating anticancer targeted therapies in INVESTIGATIONAL NEW DRUGS
  • 2009-03 Vancomycin flush as antibiotic prophylaxis for early catheter-related infections: a cost-effectiveness analysis in SUPPORTIVE CARE IN CANCER
  • 2009 Treatment of Medulloblastoma in adults in MANAGEMENT OF RARE ADULT TUMOURS
  • 2008-12 O-Mel-Inib: A Cancéro-pôle Nord-Ouest multicenter phase II trial of high-dose Imatinib mesylate in metastatic uveal melanoma in INVESTIGATIONAL NEW DRUGS
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "affiliation": [
          {
            "affiliation": {
              "id": "https://www.grid.ac/institutes/grid.452351.4", 
              "type": "Organization"
            }, 
            "isCurrent": true, 
            "type": "OrganizationRole"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.4461.7", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.410463.4", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.418189.d", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.418205.a", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.448803.3", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.5399.6", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.476192.f", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.412304.0", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.412180.e", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.16780.38", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.417988.b", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.476460.7", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.418116.b", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.418936.1", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.418037.9", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.418113.e", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.417812.9", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.417829.1", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.484651.a", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.413875.c", 
            "type": "Organization"
          }
        ], 
        "familyName": "Penel", 
        "givenName": "Nicolas", 
        "id": "sg:person.0677574257.10", 
        "identifier": {
          "name": "orcid_id", 
          "type": "PropertyValue", 
          "value": [
            "0000-0001-5243-1548"
          ]
        }, 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0677574257.10", 
          "https://orcid.org/0000-0001-5243-1548"
        ], 
        "sdDataset": "persons", 
        "sdDatePublished": "2019-03-07T14:44", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-uberresearch-data-dimensions-researchers-20181010/20181011/dim_researchers/base/researchers_488.json", 
        "type": "Person"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/person.0677574257.10'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/person.0677574257.10'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/person.0677574257.10'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/person.0677574257.10'


     

    This table displays all metadata directly associated to this object as RDF triples.

    61 TRIPLES      11 PREDICATES      33 URIs      8 LITERALS      3 BLANK NODES

    Subject Predicate Object
    1 sg:person.0677574257.10 schema:affiliation N735c926f9c0a4d608ca5cf2d19915fb8
    2 https://www.grid.ac/institutes/grid.16780.38
    3 https://www.grid.ac/institutes/grid.410463.4
    4 https://www.grid.ac/institutes/grid.412180.e
    5 https://www.grid.ac/institutes/grid.412304.0
    6 https://www.grid.ac/institutes/grid.413875.c
    7 https://www.grid.ac/institutes/grid.417812.9
    8 https://www.grid.ac/institutes/grid.417829.1
    9 https://www.grid.ac/institutes/grid.417988.b
    10 https://www.grid.ac/institutes/grid.418037.9
    11 https://www.grid.ac/institutes/grid.418113.e
    12 https://www.grid.ac/institutes/grid.418116.b
    13 https://www.grid.ac/institutes/grid.418189.d
    14 https://www.grid.ac/institutes/grid.418205.a
    15 https://www.grid.ac/institutes/grid.418936.1
    16 https://www.grid.ac/institutes/grid.4461.7
    17 https://www.grid.ac/institutes/grid.448803.3
    18 https://www.grid.ac/institutes/grid.476192.f
    19 https://www.grid.ac/institutes/grid.476460.7
    20 https://www.grid.ac/institutes/grid.484651.a
    21 https://www.grid.ac/institutes/grid.5399.6
    22 schema:familyName Penel
    23 schema:givenName Nicolas
    24 schema:identifier N6a03384d748147d49270c6a4577d76e4
    25 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0677574257.10
    26 https://orcid.org/0000-0001-5243-1548
    27 schema:sdDatePublished 2019-03-07T14:44
    28 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    29 schema:sdPublisher N99e2ae02e1f044d38f575aac6716639d
    30 sgo:license sg:explorer/license/
    31 sgo:sdDataset persons
    32 rdf:type schema:Person
    33 N6a03384d748147d49270c6a4577d76e4 schema:name orcid_id
    34 schema:value 0000-0001-5243-1548
    35 rdf:type schema:PropertyValue
    36 N735c926f9c0a4d608ca5cf2d19915fb8 schema:affiliation https://www.grid.ac/institutes/grid.452351.4
    37 sgo:isCurrent true
    38 rdf:type schema:OrganizationRole
    39 N99e2ae02e1f044d38f575aac6716639d schema:name Springer Nature - SN SciGraph project
    40 rdf:type schema:Organization
    41 https://www.grid.ac/institutes/grid.16780.38 schema:Organization
    42 https://www.grid.ac/institutes/grid.410463.4 schema:Organization
    43 https://www.grid.ac/institutes/grid.412180.e schema:Organization
    44 https://www.grid.ac/institutes/grid.412304.0 schema:Organization
    45 https://www.grid.ac/institutes/grid.413875.c schema:Organization
    46 https://www.grid.ac/institutes/grid.417812.9 schema:Organization
    47 https://www.grid.ac/institutes/grid.417829.1 schema:Organization
    48 https://www.grid.ac/institutes/grid.417988.b schema:Organization
    49 https://www.grid.ac/institutes/grid.418037.9 schema:Organization
    50 https://www.grid.ac/institutes/grid.418113.e schema:Organization
    51 https://www.grid.ac/institutes/grid.418116.b schema:Organization
    52 https://www.grid.ac/institutes/grid.418189.d schema:Organization
    53 https://www.grid.ac/institutes/grid.418205.a schema:Organization
    54 https://www.grid.ac/institutes/grid.418936.1 schema:Organization
    55 https://www.grid.ac/institutes/grid.4461.7 schema:Organization
    56 https://www.grid.ac/institutes/grid.448803.3 schema:Organization
    57 https://www.grid.ac/institutes/grid.452351.4 schema:Organization
    58 https://www.grid.ac/institutes/grid.476192.f schema:Organization
    59 https://www.grid.ac/institutes/grid.476460.7 schema:Organization
    60 https://www.grid.ac/institutes/grid.484651.a schema:Organization
    61 https://www.grid.ac/institutes/grid.5399.6 schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...